High throughput analysis of alendronate in human samples with derivatization-free hydrophilic-interactive chromatography mass spectrometry.
Alendronate
Bioequivalence
Bisphosphonate
Derivatization
Pharmacokinetics
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
17
08
2023
revised:
06
10
2023
accepted:
08
10
2023
medline:
3
11
2023
pubmed:
16
10
2023
entrez:
15
10
2023
Statut:
ppublish
Résumé
A derivatization-free hydrophilic-interactive chromatography-mass spectrometry (HILIC-MS/MS) method was developed for quantifying low levels of alendronate in human plasma. Alendronate was separated and concentrated using calcium co-precipitation and analyzed by HILIC-MS/MS, requiring only a 300 μL plasma sample for each analysis. The method is simpler, safer, and more environmentally friendly than the conventional LC-MS/MS method that requires solid-phase extraction and derivatization steps during sample pretreatment. The method was validated for selectivity, linearity, precision, accuracy, extraction recovery, matrix effect and limit of quantification. The between-run precisions were no more than 7.1 % with accuracy ranging from - 1.7-6.3 %; extraction recovery was determined to be 85.3 %; while validation results indicated that the method was suitable for accurately quantifying alendronate concentrations in the range from 0.2 to 50 ng/mL. The approach was used successfully for high throughput analysis of alendronate in more than 3700 plasma samples from 120 subjects in a bioequivalence study.
Identifiants
pubmed: 37839263
pii: S0731-7085(23)00544-7
doi: 10.1016/j.jpba.2023.115775
pii:
doi:
Substances chimiques
Alendronate
X1J18R4W8P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115775Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.